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Recently, missense mutations upstream of preproinsulin’s signal
peptide (SP) cleavage site were reported to cause mutant INS
gene-induced diabetes of youth (MIDY). Our objective was to
understand the molecular pathogenesis using metabolic labeling
and assays of proinsulin export and insulin and C-peptide pro-
duction to examine the earliest events of insulin biosynthesis,
highlighting molecular mechanisms underlying b-cell failure plus
a novel strategy that might ameliorate the MIDY syndrome. We ﬁnd
that whereas preproinsulin-A(SP23)S is efﬁciently cleaved, pro-
ducing authentic proinsulin and insulin, preproinsulin-A(SP24)D
is inefﬁciently cleaved at an improper site, producing two subpo-
pulations of molecules. Both show impaired oxidative folding and
are retained in the endoplasmic reticulum (ER). Preproinsulin-
A(SP24)D also blocks ER exit of coexpressed wild-type proinsulin,
accounting for its dominant-negative behavior. Upon increased
expression of ER–oxidoreductin-1, preproinsulin-A(SP24)D remains
blocked but oxidative folding of wild-type proinsulin improves,
accelerating its ER export and increasing wild-type insulin pro-
duction. We conclude that the efﬁciency of SP cleavage is linked
to the oxidation of (pre)proinsulin. In turn, impaired (pre)pro-
insulin oxidation affects ER export of the mutant as well as that
of coexpressed wild-type proinsulin. Improving oxidative fold-
ing of wild-type proinsulin may provide a feasible way to rescue
insulin production in patients with MIDY. Diabetes 61:828–
837, 2012
Among the many monogenic causes of diabetes(1–3), mutant insulin gene syndrome was origi-nally used to describe three autosomal-dominantmutations associated with an adult-onset, type 2
diabetes-like phenotype (4). More recently, in addition to
recessive INS gene mutations (5), new INS gene mutations
have been found to underlie a syndrome we call mutant
INS gene-induced diabetes of youth (MIDY), in which
heterozygotes develop autosomal-dominant diabetes, with
onset from neonatal life to adulthood (6–15). The MIDY
mutations cause misfolding of the insulin precursor pro-
tein (16,17), resulting in retention within the endoplasmic
reticulum (ER) of b-cells (18,19). Importantly, such mis-
folded proinsulin forms protein complexes that can in-
corporate innocent bystander proinsulin (20), impairing
the ER exit of wild-type (WT) proinsulin and decreasing
insulin production (21). Moreover, recent studies indicate
that insulin deﬁciency precedes a net loss of b-cell mass
(22,23), suggesting that this dominant-negative blockade
caused by mutants is sufﬁcient to account for initial onset
of diabetes in MIDY (24,25).
In b-cells, insulin synthesis begins with the precursor
preproinsulin, which must undergo cotranslational trans-
location into the ER, signal peptide (SP) cleavage and
downstream proinsulin folding. These earliest events are
critical to insulin biosynthesis, but they are relatively
understudied since the discovery of preproinsulin (26).
Two preproinsulin SP mutations located at or next to the
SP cleavage site have been recently reported to cause
human diabetes (2,3,6,8), which makes investigation of these
earliest events especially timely. One of them, preproinsulin-
A(SP24)D, was reported to impair preproinsulin processing
(26) and induce ER stress; yet, A(SP24)D reportedly pro-
duced no signiﬁcant adverse effect on insulin production
from a coexpressed WT allele (27). Thus, it is uncertain
why A(SP24)D should not be a recessive rather than a
dominant mutation causing severe, early onset, insulin-
deﬁcient diabetes.
In this report, we have more closely examined A(SP23)S
and A(SP24)D, both reportedly associated with human
MIDY (6,7,10,12). We ﬁnd that A(SP23)S has no detectable
biological defect and is likely to be a polymorphic variant.
By contrast, upon translocation into the ER lumen, A(SP24)D
exhibits defective SP cleavage, resulting in abnormal oxi-
dative folding of downstream proinsulin, forming disulﬁde-
linked protein complexes that are retained in the ER. We
demonstrate that A(SP24)D expression results in dominant-
negative blockade of coexpressed proinsulin-WT, a com-
mon mechanism in MIDY (20,24,25). Finally, we have
explored a potential therapeutic mechanism that, in the
presence of A(SP24)D, can improve the native oxidative
maturation of coexpressed proinsulin-WT, enhancing its
export and increasing insulin production.
RESEARCH DESIGN AND METHODS
Materials. Guinea pig anti-porcine insulin, rat insulin (#RI-13 K), and human
insulin-speciﬁc (#HI-14 K) and proinsulin-speciﬁc radioimmunoassay (#HPI-15
K) were from Millipore; rabbit anti-Myc and anti-GFP were from Immunology
Consultants Laboratories; Zysorbin was from Zymed; 35S-amino acid mixture
(Met+Cys) and pure 35S-Met were from ICN; dithiothreitol (DTT), protein
A-agarose, digitonin, N-ethylmaleimide (NEM), and radioimmunoassay (RIA)-
grade bovine serum albumin were from Sigma-Aldrich; Met/Cys-deﬁcient
Dulbecco’s modiﬁed Eagle’s medium (DMEM) and all other tissue culture
reagents were from Invitrogen. Plasmids encoding human Ero1a and Ero1b
were from Dr. P. Scherer (University of Texas Southwestern), and mouse
protein disulﬁde isomerase (PDI) was from Dr. M. Green (St. Louis University).
Human and mouse preproinsulin mutagenesis. The human INS cDNA and
mouse Ins2 cDNA with or without Myc tag as described (21) were subcloned
into pTarget and pCMS-GFP vectors. Mutations were introduced using the
QuikChange site-directed mutagenesis kit (Stratagene) and conﬁrmed by di-
rect DNA sequencing.
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Cell culture, transfection, metabolic labeling, immunoprecipitation,
SDS-PAGE, Western blotting, and ER stress response. INS1 (rat) cells,
Min6 (mouse) cells, or 293T (human) cells were plated onto 12-well plates 1 day
before transfection with Lipofectamine (Invitrogen) using 1 to 2 mg plasmid
DNA. At 48 h after transfection, cells were pulse-labeled with 35S-Met/Cys or
pure 35S-Met and chased as indicated. Cells used for analysis of (pre)pro-
insulin oxidative folding were preincubated with 20 mmol/L NEM in PBS on
ice for 10 min before lysis. Lysis buffer (1% Triton X-100, 0.1% SDS, Tris, pH
7.4) contained 2 mmol/L NEM and a proteinase inhibitor cocktail. For im-
munoprecipitation, samples were precleared with Zysorbin and immunopre-
cipitated as described previously (21). Nonreducing or reducing Tris-Tricine
urea–SDS-PAGE was performed as described (18). For Western blotting, 20 mg
total lysate protein was boiled in SDS sample buffer with or without 100 mmol/L
DTT, resolved by 4–12% NuPage, electrotransferred to nitrocellulose, and
blotted with rabbit anti-Myc followed by anti-rabbit–HRP conjugate, with de-
velopment by enhanced chemiluminescence. The BiP promoter-driven ﬁreﬂy
luciferase assay for Min6 cells 48 h posttransfection to express human
preproinsulin-WT or mutants (normalized to Renilla luciferase activity) was
performed as described (21) using the dual-luciferase reporter kit (Promega).
Partial permeabilization of plasma membranes with digitonin. After la-
beling with 35S-Cys/Met, 293T cells transfected with human preproinsulin-WT
or mutant were washed, resuspended, and incubated in 50 ml of 150 mmol/L
NaCl, 2 mmol/L CaCl2, 50 mmol/L HEPES, pH 7.5, 6 0.01% digitonin on ice for
10 min. The cells were spun at 14,000 rpm for 10 min at 4°C; the supernate was
transferred to a new tube containing 450 mL lysis buffer and the pellet lysed in
500 mL lysis buffer. Both supernate and pellet were immunoprecipitated with
anti-insulin or anti-GFP and analyzed using 4–12% NuPage.
Radioimmunoassay of WT human proinsulin and insulin. 293T cells were
cotransfected with human preproinsulin-WT and either mouse preproinsulin-WT
or mutants, plus empty vector or a vector expressing PDI or ER–oxidoreductin-1
(ERO1), at a DNA molar ratio of 1:2:3. At 40 h posttransfection, medium-bathing
transfected cells were collected for an additional 16 h and used to measure
secreted human proinsulin using the human proinsulin-speciﬁc RIA.
Min6 cells were transfected with vectors expressing human preproinsulin-
WT or mutants. At 40 h posttransfection, cells were incubated with DMEM
containing 25.5 mmol/L glucose and 10% FBS for 16 h. The media were then
collected and cells lysed with acid/ethanol (20) and human insulin measured by
human insulin-speciﬁc RIA. In parallel, duplicate wells of each transfection
were used for isolating total RNA. Human insulin mRNA levels were determined
by RT-PCR using forward primer: 59-GAACCAACACCTGTGCGGCTCAC-39 and
reverse primer: 59-CGAGGCTTCTTCTACACACCCA-39. In this way, human in-
sulin protein level was normalized to human insulin mRNA level.
FIG. 1. A(SP23)S exhibits no abnormal phenotype, whereas A(SP24)D exhibits a defect in SP cleavage and insulin production and induces ER
stress in b-cells. A: Signal sequence alignment of preproinsulins of various species. The arrow indicates the predicted signal peptide cleavage site;
the 21 residue is boxed and a Ser-SP23 (22) residue in chimpanzee preproinsulin is circled. B: MIN6 cells were transiently transfected with
plasmids encoding hProCpepMyc-WT, A(SP23)S, or A(SP24)D and lysed after 48 h posttransfection, and 20 mg total protein was used for anti-Myc
Western blot as described in RESEARCH DESIGN AND METHODS. C: MIN6 cells were transiently transfected with human preproinsulin-WT, A(SP23)S, or
A(SP24)D plasmids. At 40 h posttransfection, the cells were incubated with fresh DMEM medium containing 25.5 mmol/L glucose and 10% FBS for
additional 16 h; the media were collected and cells lysed as in RESEARCH DESIGN AND METHODS. Human insulin in the lysates (black bars) and media
(white bars) were quantiﬁed using human-speciﬁc insulin RIA normalized to human-speciﬁc insulin mRNA (a measure of the efﬁciency of insulin
production from the transfected translation product). Results shown are mean values 6 SD from three independent experiments. *P < 0.01
compared with preproinsulin-WT or A(SP23)S. D: Min6 cells cotransfected to express BiP promoter-ﬁreﬂy luciferase, CMV promoter-driven R.
luciferase, and preproinsulin-WT or mutants were lysed at 48 h posttransfection, and the ratio of ﬁreﬂy/R. luciferase was measured. Cells
expressing WT proinsulin or empty vector (EV) served as a negative control. Results are expressed as mean 6 SD from three independent
experiments. *P < 0.05 compared with preproinsulin-WT.
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Statistical analysis. Statistical analyses were carried out by ANOVA fol-
lowed by Bonferroni multiple comparison test using GraphPad Prism 5. Data
are presented as means 6 SD. A P value of ,0.05 was taken as statistically
signiﬁcant.
RESULTS
SP cleavage of human preproinsulin-A(SP23)S and
A(SP24)D. Evolutionarily, the preproinsulin SP diverges
more in sequence than does the insulin B-chain or A-chain
(28). In tetrapods, residue A(SP24) predominates at the
cleavage site (residue “21”), whereas there is considerable
natural variation at the penultimate “22” position (Fig. 1A).
In chimpanzee, S(SP23) predominates (Fig. 1A), and there
is a polymorphic variation in this position even within the
human genome (29). Thus, it was of interest to further in-
vestigate the physiological signiﬁcance of both A(SP23)S
and A(SP24)D substitutions.
In MIN6 pancreatic b-cells transfected to express Myc-
tagged human preproinsulin [preProCpepMyc (21)], A(SP24)D
was predominantly uncleaved, with a minor cleaved band
migrating near ProCpepMyc-WT (Fig. 1B). Impaired ef-
ﬁciency of SP cleavage (Fig. 1B) can directly account for
decreased human insulin production (Fig. 1C). By contrast,
A(SP23)S showed no defect of SP cleavage or human
insulin production (Fig. 1B and C). Moreover, A(SP24)D
induced ER stress in Min6 cells, whereas the ER stress re-
sponse for A(SP23)S was similar to that for preproinsulin-
WT (Fig. 1D). In 293T cells, newly synthesized A(SP23)S
was rapidly processed to proinsulin and secreted, exactly
like WT, whereas A(SP24)D showed little preproinsulin
processing or secretion (Fig. 2A). From multiple such
experiments, #10% of A(SP24)D underwent SP cleavage
(Fig. 2B). We examined the subsequent fate of newly syn-
thesized mutant preproinsulin for up to 4 h of chase.
Although secretion of either uncleaved or SP-cleaved
A(SP24)D was negligible, there was intracellular loss of
A(SP24)D, some of which was clearly blocked by the
proteasome inhibitor MG132 (Fig. 2C). Although the data
suggest ER-associated degradation (ERAD) of A(SP24)D
at steady state, A(SP24)D showed substantial accumula-
tion in b-cells (Fig. 1B). Thus, A(SP23)S exhibits no defect
of SP cleavage or insulin production, whereas A(SP24)D
exhibits impaired SP cleavage, intracellular retention, at
least partial ERAD, activation of ER stress response, and
blocked insulin production.
Translocation of preproinsulin-A(SP24)D across the
ER membrane. Conceivably, failed SP cleavage could
reﬂect failure of preproinsulin translocation across the ER
membrane (30). We used digitonin to partially permeabilize
the plasma membrane while keeping organelle membranes
intact (31) in cells coexpressing recombinant preproinsulin
and cytosolic green ﬂuorescent protein (GFP); upon per-
meabilization and centrifugation, .50% of cytosolic GFP
was relocated from pellet to supernate, whereas both WT
and A(SP24)D remained exclusively in the pellet (Fig. 3A).
Thus, A(SP24)D is not free in the cytosol, implying its as-
sociation with the ER. It is known that the preproinsulin SP
plus the ﬁrst 14 residues of proinsulin B-chain are sufﬁcient
to direct the downstream translation product into the ER
lumen (32). To conﬁrm that this is the case for A(SP24)D, we
engineered the A(Cpep18)N substitution into the C-peptide
(Fig. 3B, top) to create an artiﬁcial N-linked glycosylation
site that can be used to establish that at least 76 residues
of nascent preproinsulin polypeptide have accessed the lu-
minal side of the ER. When combined with the fact that hu-
man proinsulin has no methionine residues (i.e., pure 35S-Met
can label only preproinsulin; 35S-proinsulin labeling requires
35S-Cys), we found that essentially all molecules of both
proinsulin-WT (35S-Cys/Met) and A(SP24)D (either 35S-Met
or 35S-Cys/Met) became available in the ER lumen, as es-
tablished by N-linked glycosylation that could be deglycosy-
lated with PNGase F (Fig. 3B). Thus, essentially all molecules
of A(SP24)D undergo ER translocation.
Disulﬁde bonding within uncleaved preproinsulin. To
our knowledge, no studies have previously examined the
relationship between SP cleavage and oxidative folding of
FIG. 2. SP cleavage and ER export of A(SP23)S and A(SP24)D. A: Transfected 293T expressing human preproinsulin-WT or mutants were pulse-
labeled with 35S-Cys/Met for 10 min followed by 0 or 90 min chase. Cell lysates (C) and chase media (M) were immunoprecipitated with anti-insulin
and analyzed using 4–12% NuPage under reducing conditions. B: From repeat experiments like that shown in A, without chase, the uncleaved and
processed preproinsulin bands were quantiﬁed by scanning densitometry (6 SD). P < 0.01 compared to either WT or A(SP23)S. C: Transfected
293T cells expressing WT or A(SP24)D were pulse-labeled with 35S-Cys/Met for 30 min followed by 0, 1, or 4 h chase with or without 10 mmol/L
MG132. The cell lysates and chase media were combined and immunoprecipitated with anti-insulin and analyzed using 4–12% NuPage under re-
ducing conditions.
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preproinsulin within the ER. We used nonreducing Tris-
Tricine urea–SDS-PAGE (16) to examine disulﬁde bond
formation in recombinant newly synthesized preproinsulin.
Uncleaved preproinsulin-WT (labeled with 35S-Met) appears
fully reduced (Fig. 4A, lane 2). Upon SP removal, proinsulin-
WT (labeled with 35S-Cys/Met) may begin as a fully re-
duced species (Fig. 4A, lane 1, arrow) but proceeds to
native and isomeric oxidized proinsulin (lower bands).
Within 10 min, reduced (pre)proinsulin nearly vanished,
and oxidized native proinsulin became enriched (Fig. 4B,
lane 2), indicating both rapid SP cleavage and downstream
proinsulin folding.
For A(SP24)D, the sequence of early events appeared al-
tered: newly synthesized preproinsulin-A(SP24)D (35S-Met–
labeled) started to become oxidized (Fig. 4A, lanes 7 and 8),
and this increased after 10 min (Fig. 4B, lane 8). By
comparing the recovery of fully reduced preproinsulin-
A(SP24)D by nonreducing gel versus total preproinsulin
recovered under reducing conditions, we calculated (from
multiple experiments) that 42 6 2.7% of preproinsulin-
A(SP24)D had oxidized (either properly or improperly, see
below) at the zero chase time. The oxidized fraction of
preproinsulin-A(SP24)D was 61% by 10 min of chase; 86%
by 30 min of chase; and 90% under steady-state conditions
by Western blotting (Fig. 4C, right). By contrast, proinsulin-WT
was .90% oxidized at the zero chase time, and there was
essentially no fully reduced proinsulin-WT remaining after
10 min (Fig. 4B). Under steady-state conditions, #10% oxi-
dized A(SP24)D remains as monomer recovered under
nonreducing conditions (Fig. 4C, compare lanes 3 and 4),
indicating that the majority forms disulﬁde-linked protein
complexes. Most importantly, in b-cells, A(SP24)D coim-
munoprecipitated coexpressed proinsulin-WT, which was
detected only under reducing conditions; thus, this pro-
insulin-WT must also have been recruited into disulﬁde-
linked complexes (Fig. 4D). Altogether, the data in Figs. 3
and 4 establish that impaired SP cleavage triggers defective
oxidative folding within the ER, leaving exposed thiols on
preproinsulin that could create cellular problems by par-
ticipating in inappropriate intermolecular thiol attack.
Inappropriate SP cleavage of preproinsulin-A(SP24)D
and dominant-negative blockade of proinsulin-WT.
Using the SignalP-3.0 computer-based algorithm, we noted
that whereas human preproinsulin-WT uses the AAA-
proinsulin sequence to generate proinsulin beginning with
the appropriate F(B1) residue, the A(SP24)D sequence pre-
dicts SP cleavage at low efﬁciency, generating a minor
portion of AD-Proins that includes two extra residues
preceding the proinsulin B-chain (Fig. 5A). We therefore
designed three additional preproinsulin mutants (AAAAD-
Proins, AAAMD-Proins, and AMAD-Proins) intended to
interrogate the location of the preproinsulin cleavage site
while ﬁnding a high-efﬁciency means to generate the aber-
rant AD-Proins cleavage product (Fig. 5A). By SDS-PAGE/
autoradiography after metabolic labeling with 35S-Cys/Met,
unlike the inefﬁcient SP cleavage of A(SP24)D (Fig. 5B,
lanes 3 and 4), other bioengineered preproinsulins un-
derwent efﬁcient (but aberrant) SP cleavage. In Fig. 5B,
a comparison of lanes 2, 4, 6, 8, and 10 (each including
35S-Cys label) showed the presence of a cleaved band in
every instance. However, when comparing lanes 3, 5, and
7 (Fig. 5B) labeled with pure 35S-Met, the cleaved band
became undetectable except in lane 7 (AAAMD-Proins),
when methionine was still found to be contained within
the product that must have been cleaved upstream of the
Met residue. By contrast, in lane 9 (AMAD-Proins; Fig. 5B)
the cleaved product had lost the Met residue (i.e., a cleav-
age site less than three residues upstream from the normal
site but containing at least two residues from the normal
site). These observations precisely match the cleavage
sites predicted. Regardless of whether the cleavage reac-
tion occurred at low efﬁciency or high efﬁciency, the ab-
errant proinsulins bearing two extra NH2-terminal amino
acids in every instance failed to be secreted normally (Fig.
5C). Thus, ﬁdelity of SP cleavage, exposing the critical
proinsulin NH2-terminal arm, including phenylalanine-B1
(33), is crucial to normal proinsulin folding and export
from the ER.
Because A(SP24)D forms aberrant disulﬁde-linked pro-
tein complexes (Fig. 4C) that include coexpressed proinsulin-
WT (Fig. 4D), we made A(SP24)D-DelCys (in which all six
cysteines were mutated) to test for dominant-negative
behavior. Interestingly, most of the blockade of WT
proinsulin secretion was lost when thiols were elimi-
nated from the A(SP24)D mutant (Fig. 6A). These data
support the concept of thiol attack as a mechanism of
dominant-negative behavior of A(SP24)D (i.e., precisely
the danger mechanism that has been proposed for MIDY)
(21,25).
Heterozygous patients bearing INS gene mutations that
cause decreased insulin biosynthesis from the mutant allele
FIG. 3. Translocation of preproinsulin-A(SP24)D across the ER mem-
brane. A: At 40 h posttransfection, 293T cells coexpressing cytosolic
GFP and preproinsulin-WT or -A(SP24)D were pulse-labeled with
35S-Cys/Met for 15min and then treated with 0.01% digitonin on ice for 10
min to permeabilize the plasma membrane, which liberates a major
fraction of cytosolic GFP. Cells were then sedimented at 14,000 rpm at
4°C for 10 min and each pellet (P) and supernate (S) analyzed se-
quentially by anti-insulin and anti-GFP immunoprecipitation, 4–12%
NuPage, under reducing conditions and autoradiography. B: The 18th
residue of human preproinsulin C-peptide was mutated from Ala to Asn
to create an N-linked glycosylation site. At 40 h posttransfection, 293T
cells expressing human preproinsulin-A(Cpep18)N bearing or lacking
the A(SP24)D mutation were pulse-labeled with either pure 35S-Met or
mixed 35S-Cys/Met for 15 min before lysis and immunoprecipitation
with anti-insulin. Immunoprecipitates were split in half and either
digested (+) or mock digested (2) with PNGase F at 37°C for 1 h before
analysis by 4–12% NuPage under reducing conditions. At this exposure,
preproinsulin-WT is not detected with pure 35S-Met, indicating that the
vast majority of molecules have already undergone SP cleavage;
thus, the same sample labeled with 35S-Cys/Met indicates glycosy-
lated (Glyco-Proins) or deglycosylated proinsulin (Proins). However,
A(SP24)D remains labeled with pure 35S-Met, indicating the positions
of glycosylated (Glyco-preProins) or deglycosylated preproinsulins
(preProins).
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do not develop diabetes (5). Thus, decreased insulin pro-
duction from A(SP24)D itself cannot account for diabetes
in heterozygous patients. To explore this further, indivi-
dually epitope-tagged and preproinsulin partners were
coexpressed in b-cells. A preProCpepMyc construct, either
bearing or not bearing the A(SP24)D mutation, was coex-
pressed in INS1 cells along with preProCpepGFP, a re-
porter of WT proinsulin trafﬁcking and processing (20,24).
Although new synthesis of preProCpepGFP was unaffected
by coexpression of A(SP24)D, the production of mature
FIG. 4. The kinetics of SP cleavage and disulﬁde bond formation. A: At 40 h posttransfection, 293T cells expressing human preproinsulin-WT or
-A(SP24)D were pulse-labeled for 10 min with either 35S-Cys/Met or pure 35S-Met, as indicated. The cells were pretreated with 20 mmol/L NEM in
PBS on ice for 10 min before lysis and immunoprecipitation with anti-insulin. The immunoprecipitates were analyzed using Tris-Tricine urea–SDS-
PAGE under nonreducing and reducing conditions, as indicated. The positions of both oxidized and reduced forms of preproinsulin (preProins) and
proinsulin (Proins) are indicated. B: At 40 h posttransfection, 293T cells expressing human preproinsulin WT or A(SP24)D were pulse-labeled
with 35S-Cys/Met for 10 min and chased for 0 or 10 min. Newly synthesized preproinsulin (preProins) and proinsulin (Proins) were analyzed as in
A. C: 293T cells transiently transfected to express preProCpepMyc-WT or the same construct bearing A(SP24)D were lysed at 48 h post-
transfection, and 20 mg total proteins was resolved by 4–12% NuPage under nonreducing and reducing conditions, as indicated, followed by anti-
Myc Western blotting as described in RESEARCH DESIGN AND METHODS. D: INS1 cells transfected with preProCpepMyc-A(SP24)D were pulse-labeled
with 35S-Cys/Met for 30 min. The cells were lysed and immunoprecipitated with anti-Myc and analyzed as in A.
INSULIN SIGNAL PEPTIDE MUTATIONS
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human insulin, as measured by accumulation of the pro-
cessed CpepGFP over 20 h of continuous metabolic label-
ing, was clearly inhibited upon coexpression of the mutant
(Fig. 6B). These data link mutant A(SP24)D expression to
insulin deﬁciency derived from the WT proinsulin allele.
Whereas the AAAAD-Proins construct exclusively forms
miscleaved AD-Proinsulin (Fig. 5), we also engineered
a preproinsulin (PFD-Proins, Fig. 5A) that cannot be
cleaved at all by signal peptidase as measured either by
pulse-labeling (Fig. 5B, lane 11) or at steady state (Fig.
6C). Individually, these two constructs should be able to
test the relative dominant-negative contributions derived
from the actual A(SP24)D mutant which, after 1–4 h chase,
can be detected as both forms (Fig. 2C).
First, to test whether miscleaved AD-Proins was a po-
tent dominant-negative, we coexpressed progressively
decreasing doses of AAAAD-Proins with bystander pre-
ProCpepMyc-WT to emulate the small quantities of AD-
Proinsulin typically synthesized from A(SP24)D. At all
expression levels, untagged AD-Proinsulin itself was im-
paired in the secretory pathway, but only at the highest
expression levels did AD-Proinsulin inhibit export of coex-
pressed bystander ProCpepMyc-WT (Fig. 6D, top). However,
at low expression levels [all of which are higher than that
generated from A(SP24)D], AD-Proinsulin could no longer
block secretion of ProCpepMyc-WT (Fig. 6D, bottom).
Next, we found that newly synthesized PFD-Proins also
could not be secreted; but more importantly, uncleaved
PFD-Proins efﬁciently blocked in trans the ER export of
coexpressed proinsulin-WT (Fig. 6E). Thus, PFD-Proins
completely emulated the dominant-negative effects of
A(SP24)D. Taken together, the data in Fig. 6 strongly suggest
that it is the improperly oxidized full-length preproinsulin-
A(SP24)D, and not the miscleaved AD-Proins product de-
rived from A(SP24)D, that is primarily responsible for
dominant-negative blockade of coexpressed proinsulin-WT
in patients with MIDY.
Partial rescue of proinsulin-WT from dominant-
negative blockade of A(SP24)D. We have previously
demonstrated that MIDY mutants selectively interfere with
the oxidative folding to the native state of innocent by-
stander proinsulin-WT molecules, and promote their ERAD
(21). We reasoned that conditions accelerating native
disulﬁde bond formation in proinsulin-WT might help these
molecules escape blockade caused by A(SP24)D (and
other MIDY mutants). Recent reports indicate that mem-
bers of the ERO1 family promote formation of proinsulin
disulﬁde bonds (34,35). We therefore explored whether
overexpression of ERO1 [or PDI (36)] could help to rescue
human proinsulin-WT from blockade by either mouse
Akita proinsulin [another MIDY mutant (20,21)] or mouse
preproinsulin-A(SP24)D. Using a human-proinsulin spe-
ciﬁc RIA, we found that increased expression of ERO1
(either a or b), but not PDI, showed rescue activity for
export of proinsulin-WT (Fig. 7A). To conﬁrm this rescue
effect in b-cells, we coexpressed human preproinsulin-WT
with mouse preproinsulin-A(SP24)D, which lowered the
human insulin content of transfected INS1 cells by .70%
FIG. 5. Inappropriate SP cleavage of A(SP24)D and engineered preproinsulins. A: WT or engineered human preproinsulins (with the names in-
dicated in the column at left) show predicted SP cleavage sites are based on the SignalP 3.0 algorithm (http://www.cbs.dtu.dk/services/SignalP/). SP
cleavage (black arrowheads) leaves predicted additional residues attached to the NH2 terminus of the proinsulin B-chain. B: At 48 h post-
transfection, 293T cells expressing human preproinsulin-WT (AAA-Proins in this panel) or mutants as indicated were pulse-labeled for 15 min with either
pure 35S-Met or 35S-Met/Cys as indicated. Cell lysates were immunoprecipitated with anti-insulin and analyzed using 4–12% NuPage under reducing
conditions, followed by autoradiography. C: Transfected 293T cells were labeled with 35S-Met/Cys for 15 min and chased for 150 min. The cell
lysates (C) and chase media (M) were immunoprecipitated and analyzed as in B. (A high-quality color representation of this ﬁgure is available in
the online issue.)
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(Fig. 7B). However, in cells with simultaneously increased
expression of ERO1a or ERO1b, human insulin content
doubled (Fig. 7B). To independently validate these RIA
results, we performed pulse-chase experiments like those
shown in Fig. 6E. Once again, A(SP24)D blocked in trans
the export of coexpressed proinsulin-WT (Fig. 7C, lane 7).
However, in cells with increased expression of ERO1a, the
behavior of A(SP24)D itself was unaffected, whereas ex-
port of coexpressed proinsulin-WT was partially rescued
(Fig. 7C, lane 13). Similar results were obtained upon in-
creased expression of ERO1b (not shown).
To explore further the mechanism of ERO1-mediated
rescue of proinsulin-WT, we examined the recovery of the
native disulﬁde isoform of newly synthesized proinsulin-
WT relative to total proinsulin-WT recovery under re-
ducing conditions (21). In the presence of A(SP24)D, the
oxidative maturation of proinsulin-WT to the native state
was signiﬁcantly decreased (Fig. 8A, open bars). However,
upon increased expression of ERO1b, the recovery of native
disulﬁde-bonded proinsulin-WT was restored despite the
presence of coexpressed A(SP24)D (Fig. 8A, far right black
bar). Moreover, ﬁnal recovery of proinsulin-WT was greatly
increased in cells with increased ERO1b expression (Fig.
8B). Thus, despite presence of a coexpressed MIDY mutant,
in cells with increased expression of ERO1, coexpressed
proinsulin-WT exhibited improved folding and decreased
ERAD (Fig. 8), explaining its secretion rescue (Fig. 7).
DISCUSSION
Point mutations adjacent to the SP cleavage site of pre-
proteins may impair SP cleavage (37–39) and downstream
folding (40) and can cause ER stress and cytotoxicity (41).
In this report, we have investigated the biological behav-
iors of preproinsulin-A(SP23)S and A(SP24)D. These
mutants provide a window into understanding the earliest
steps of insulin biosynthesis. Unfortunately for patients
expressing A(SP24)D, a series of pathological events go
well beyond the defect in SP cleavage with failure to
provide the critical free NH2-terminal phenylalanine-B1
(33), impairing oxidation of the natural insulin disulﬁde
bonds and creating a miscleaved SP, resulting in the ER
retention of both forms of the mutant protein, blocking in
trans the coexpressed proinsulin-WT from the normal INS
gene allele and thereby profoundly inhibiting b-cell insulin
production as well as induction of ER stress. On the pos-
itive side, we have developed a therapeutic maneuver that
may minimize the dominant-negative effects of MIDY
mutants.
All available evidence suggests that A(SP23)S is cleaved
with normal efﬁciency (Fig. 2A and B) and ﬁdelity to
generate authentic proinsulin (Fig. 1B) and insulin (Fig.
1C) with no net ER stress beyond that seen for pre-
proinsulin-WT (Fig. 1D). As serine is the native residue in
this position in chimpanzee (Fig. 1A) and is the site of
polymorphic variation in humans (29), we propose that in
FIG. 6. Dominant-negative blockade of proinsulin-WT caused by preproinsulin-A(SP24)D, miscleaved proinsulin, and uncleaved preproinsulin. A:
293T cells were cotransfected to express human preproins-WT with either mouse preproins-WT, A(SP24)D, or A(SP24)D-DelCys [in which all
cysteines of A(SP24)D were mutated (21)] at a DNA ratio of 1:2. Beginning at 30 h posttransfection, cells were incubated with DMEM containing
25.5 mmol/L glucose plus 10% FBS for additional 16 h. Media were collected, and a human proinsulin-speciﬁc RIA was used to measure secretion of
coexpressed human proinsulin-WT. The secretion of human proinsulin coexpressed with mouse preproins-WT served as a positive control (i.e., set
to 100%). Results are shown as mean 6 SD from three independent experiments. B: INS1 cells cotransfected with preProCpepGFP-WT with either
preProCpepMyc-WT or A(SP24)D (at a DNA molar ratio of 1:2) were labeled for either 0.5 or 20 h as indicated. The cell lysates (C) and media (M)
were immunoprecipitated with anti-GFP and analyzed under reducing conditions. C: INS1 cells transfected to express preProCpepMyc-WT,
A(SP24)D, or PFD were lysed at 48 h posttransfection. The cell lysates were resolved by 4–12% NuPage under reducing conditions. The proteins
were electrotransferred to nitrocellulose and immunoblotted with anti-Myc antibody. D: 293T cells cotransfected with preProCpepMyc-WT and
untagged AAAAD-Proins (processed to AD-Proins; see Fig. 5A) at a range of DNA ratios (indicated below) were pulse-labeled with 35S-Cys/Met for
30 min and chased for 0 or 2 h. Cell lysates (C) and collected chase media (M) were immunoprecipitated with anti-insulin and analyzed under
reducing conditions. E: 293T cells cotransfected with untagged preproinsulin-WT (processed to Proins) and preProCpepMyc-WT, A(SP24)D,
or PFD were pulse-labeled with 35S-Cys/Met for 30 min and chased for 0 or 3 h. Cell lysates (C) and collected chase media (M) were analyzed
as in D.
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spite of our earlier report (12), impaired preproinsulin SP
cleavage and proinsulin misfolding are not operative for
this particular variant. We cannot exclude that A(SP23)S
might cause diabetes through a different mechanism. By
contrast, although A(SP24)D is successfully translocated
across the ER membrane (Fig. 3), it is inefﬁciently pro-
cessed at an inappropriate SP cleavage site, generating
a small subpopulation of miscleaved AD-Proins mole-
cules (Figs. 1, 2, and 5–7). Both uncleaved and miscleaved
A(SP24)D are retained intracellularly (Fig. 2A) and undergo
ERAD (Fig. 2C), suggesting that they are misfolded. Never-
theless, at steady state, a major subpopulation of uncleaved
A(SP24)D (along with the smaller subpopulation of SP
cleaved) molecules accumulates in the ER (Fig. 1B), acti-
vating an ER stress response (Fig. 1D).
The half-life of preproinsulin-WT is exceedingly short,
making it technically difﬁcult to follow uncleaved pre-
proinsulin in live cells (Fig. 4B). Cleavage by signal pep-
tidase generally requires that 60–80 amino acids of the
nascent polypeptide are cotranslationally translocated
(42), which represents most of the preproinsulin molecule.
What the A(SP24)D demonstrates is that preproinsulin Cys
residues can be exposed to the oxidative environment of
the ER even before SP cleavage (Fig. 4). To our knowl-
edge, this is the ﬁrst study to directly examine oxidative
folding of preproinsulin in the ER. Normally, uncleaved
preproinsulin-WT is fully reduced, and, upon SP removal,
proinsulin begins to quickly form both native and isomeric
disulﬁde bonds (Fig. 4A and B). However, under con-
ditions in which normal SP cleavage is interrupted [e.g., in
A(SP24)D], uncleaved preproinsulin exhibits delayed and
abnormal oxidative folding (Fig. 4A and B), causing the
formation of disulﬁde-linked complexes (Fig. 4C), which
also entraps coexpressed proinsulin-WT (Fig. 4D).
We have previously shown that acute ER stress is not
itself sufﬁcient to block export of coexpressed WT INS
gene product (21). Moreover, recent studies indicate that
in MIDY, insulin deﬁciency precedes a net loss of b-cells
(22,23). In this report, we demonstrate that A(SP24)D
blocks the export of coexpressed proinsulin-WT (Fig. 6)
and thereby decreases insulin production (Figs. 6A and 7B,
open bar), which may be sufﬁcient to account for initiation
of insulin deﬁciency in patients with MIDY. The evidence
suggests that it is primarily the uncleaved preproinsulin
subfraction rather than the minor misfolded AD-Proins
subfraction (Fig. 6D and E) that drives the dominant-negative
insulin secretory behavior in patients bearing A(SP24)D.
Studies in humans suggest that one fully functional INS
gene allele may be sufﬁcient to maintain normoglycemia
(5). We therefore reasoned that rescuing proinsulin-WT
from dominant-negative blockade might restore insulin
production to rescue from diabetes in MIDY. With this in
mind, we have made a ﬁrst attempt at a molecular thera-
peutic approach to rescue proinsulin-WT export in the
FIG. 7. Dominant-negative blockade of human proinsulin by A(SP24)D is partially rescued by increased expression of ERO1. A: At 48 h post-
transfection, media bathing 293T cells coexpressing human preproinsulin-WT, one of the mouse preproins-[WT, C(A7)Y, or A(SP24)D], and empty
vector (EV), PDI, or ERO1 (at a DNA molar ratio of 1:2:3) were collected for 16 h. Secreted human proinsulin was measured using a human-speciﬁc
proinsulin RIA. Secretion of human proinsulin in the presence of mouse proinsulin-WT and empty vector was set to 100%. B: INS1 cells coex-
pressing human preproinsulin and mouse preproinsulin-A(SP24)D plus ERO1a or ERO1b (at a DNA molar ratio of 1:3:4) were lysed with acid/
ethanol to measure human insulin content using human-speciﬁc insulin RIA. The human insulin content of cells cotransfected with WT human and
mouse preproinsulins was set to 100%. C: At 48 h posttransfection, 293T cells coexpressing preproinsulin-WT and either preProCpepMyc-WT
(processed to Myc-tagged Proins) or preProCpepMyc-A(SP24)D (shown as Myc-tagged preProins) plus empty vector (Control) or ERO1a (at
a DNA molar ratio of 1:2:3) were pulse-labeled with 35S-Cys/Met for 30 min and chased for 0 or 3 h. Newly synthesized (pre)proinsulins from cell
lysates (C) and chase media (M) were immunoprecipitated with anti-insulin, resolved by Tris-Tricine urea–SDS-PAGE under reducing conditions,
and analyzed by autoradiography.
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presence of A(SP24)D; speciﬁcally searching for ways,
without repairing the misfolding of MIDY mutants, that
might enhance proinsulin-WT folding and ER export in
order to limit its participation in aberrant protein complex
formation in the ER (20). Formation of proinsulin’s three
disulﬁde bonds may occur via transfer of reducing equiv-
alents to ER oxidoreductases and from there to the cytosol
via ERO1; recently, Zito et al. (34) established that the
diabetic phenotype of Akita mice is exacerbated upon loss
of ERO1b. Conceivably, increased ERO1 or PDI expres-
sion might promote oxidative folding of proinsulin-WT.
However, whereas increased PDI expression has been
found to diminish glucose-stimulated insulin secretion and
induce ER stress with accumulation of proinsulin in the
ER (36), increased ERO1 expression promotes proinsulin-
WT export through the secretory pathway (Fig. 7A and C),
increasing insulin production (Fig. 7B). The simplest ex-
planation for the increased insulin production is en-
hancement of oxidative folding of proinsulin-WT (Fig. 8A),
decreasing its participation in disulﬁde-linked complexes
(Fig. 8A), decreasing its ERAD (Fig. 8B), and increasing
export of proinsulin-WT from the ER (Fig. 7).
Little progress has been made in the development of
treatments for ER stress-related pancreatic b-cell failure.
The ideas developed in this report suggest that enhancing
the oxidative folding and export of proinsulin-WT may be
a feasible way to restore insulin production in heterozy-
gous MIDY patients. Several laboratories around the world
have been working on small molecules that can manipu-
late the level and/or activity of ERO1b, and this may be
a useful way forward. Moreover, it will be important to
further explore the ratio of misfolded to total proinsulin
forms, to understand the threshold of misfolding that is
needed to trigger onset of insulin-deﬁciency and diabetes
(23), and the means to raise that threshold by protecting
bystander proinsulin export for insulin production and
glucose homeostasis.
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